Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q2 2023 · 10-Q
Revenue$126.05M$126.05M−10.5% vs Q2 2022 Net Income-$57.42M-$57.42MN/M vs Q2 2022 EPS Diluted-$0.54-$0.54N/M vs Q2 2022 Gross Profit$92,033,000−18.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow-$22,737,000N/M Free Cash Flowderived-$29,668,000N/M Margins · derivedGross margin73.0%−6.8 pt vs Q2 2022
Operating margin-49.7%−34.7 pt vs Q2 2022
Net margin-45.6%−28.5 pt vs Q2 2022
ended Jun 30, 2023 · filed Jul 27, 2023 · 27 d after period end